Navigation Links
Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
Date:8/9/2012

ALLEGAN, Mich., Aug. 9, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for clobetasol propionate shampoo, 0.05%, the generic equivalent  of Clobex® Shampoo. Perrigo will commence shipment of the product immediately.  

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO)

Clobetasol propionate shampoo, 0.05%, is indicated for the treatment of moderate to severe scalp psoriasis. Brand and Generic annual sales were approximately $57 million, as measured by Wolters Kluwer Health.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another example of our Rx team's commitment to launching difficult to manufacture extended topical products. We are excited to market this product and are dedicated to making quality healthcare more affordable."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 


'/>"/>
SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
2. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
3. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
4. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
5. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
6. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
7. Perrigo Company To Present At The William Blair Growth Stock Conference
8. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
9. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
10. Nephros Receives 510(k) Clearance for Hemodiafiltration System
11. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... , May 11, 2017  Thornhill Research ... has been awarded an $8,049,024 USD five-year, firm-fixed-priced, ... through the Canadian Commercial Corporation (CCC) ( ... Anesthesia Systems to administer general anesthesia to patients ... "The US Marine Corps have been ...
(Date:5/10/2017)... May 10, 2017 CSSi, the global leader ... clinical research industry, is proud to announce the launch ... new website features both enriched content and a customized ... enhances the company,s already well-established position as the top ... "After many months of hard work, we are ...
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
Breaking Medicine Technology:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Medic ... Kids: The Surprising Truth about Pediatric Septic Shock” hosted by the Journal of Emergency ... at 2 p.m. Eastern time, will be presented by Captain Rommie Duckworth, LP, a ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after ... Public Television. “Informed” brings the public important topics from all aspects of life, and ... feet and issues surrounding feet and ankles. , Podiatry is essential to people’s overall ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® Diagnostics, Inc., ... today it had completed the first phase of building a global distribution network. ... of world (ROW) authorized dealers specializing in polysomnography accessories. The company plans ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... for exercise professionals, is pleased to announce the organization’s Certified Strength Coach credential ... NCSF Certified Strength Coach (CSC) program validates the competency of qualified candidates for ...
Breaking Medicine News(10 mins):